Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TKT | P29401 | 14/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6823168 | 0.85 | TKT (0.40) | TKTALDH1A1HSP90AA1 | |
| Bromide SCHEMBL3853203 | 0.84 | TKT (0.48) | TKTHSP90AA1 | |
| Bromide SCHEMBL8941023 | 0.81 | TKT (0.54) | TKTHSP90AA1 | |
| Bromide SCHEMBL447562 | 0.80 | TKT (0.52) | TKTHSP90AA1 | |
| SCHEMBL2026240 | 0.78 | TKT (0.54) | TKTHSP90AA1 | |
| Albitiazolium SCHEMBL2017697 | 0.77 | TKT (0.50) | TKTHSP90AA1 | |
| SCHEMBL20759121 | 0.77 | TKT (0.50) | TKTHSP90AA1 | |
| Hydrochloric Acid SCHEMBL7760396 | 0.76 | TKT (0.52) | TKTHSP90AA1 | |
| Iodide SCHEMBL1779438 | 0.76 | TKT (0.52) | TKTHSP90AA1 | |
| SCHEMBL6936136 | 0.73 | TKT (0.45) | TKTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070099892-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2007-05-03 | — | — | US | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1305024-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON INC (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1353669-A4 | METHOD FOR TREATING GLAUCOMA IB | ALTEON INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050032865-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | WAGLE DILIP R (IN) | 2005-02-10 | — | — | US | disclosed |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | SYNVISTA THERAPEUTICS, INC. | 2004-11-25 | — | — | US | disclosed |
| EP-1353669-A1 | METHOD FOR TREATING GLAUCOMA IB | Alteon, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| US-6610716-B2 | Improving elasticity or reducing wrinkles of a skin, for example; advanced glycosylation endproducts\" or AGEs | ALTEON INCORPORATED | 2003-08-26 | — | — | US | disclosed |
| EP-1305024-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | Alteon, Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020103182-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002053158-A1 | METHOD FOR TREATING GLAUCOMA IB | ALTEON, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002007725-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | MMP1, COL1A1, COL2A1 | TKT 2543/4885ALDH1A1 175/4885HSP90AA1 265/4885 |
| US-20020103182-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | ABAT, TTR, TUFM | TKT 873/4885ALDH1A1 2552/4885HSP90AA1 100/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | TKT 4337/4885ALDH1A1 366/4885HSP90AA1 1433/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | TKT 3527/4885ALDH1A1 204/4885HSP90AA1 516/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | TKT 2777/4885ALDH1A1 402/4885HSP90AA1 1526/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | TKT 2413/4885ALDH1A1 261/4885HSP90AA1 446/4885 |
| US-20050032865-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | ABAT, TUFM, TTR | TKT 825/4885ALDH1A1 3194/4885HSP90AA1 113/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | TKT 2032/4885ALDH1A1 448/4885HSP90AA1 86/4885 |
| US-20070099892-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | ABAT, TUFM, TTR | TKT 825/4885ALDH1A1 3194/4885HSP90AA1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.